Consolidated Statements of Non-Controlling Interest and Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Silver Creek Series B Preferred Stock [Member]	Non-controlling Interest [Member]	Non-controlling Interest [Member] Silver Creek Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Silver Creek Series B Preferred Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$ (6,517)		$ 97		$ 958	$ 434,679		$ (38)	$ (442,116)
Balance (in shares) at Dec. 31, 2012					95,825
Exercise of stock options and common stock warrants	2,036				$ 9	2,027
Exercise of stock options and common stock warrants (shares)					948
Stock-based compensation	10,733					10,733
Issuance of common stock in a public offering, net of issuance costs	26,716				$ 58	26,658
Issuance of common stock in a public offering, net of issuance costs (shares)					5,750
Conversion option of convertible senior notes	51,875					51,875
Conversion of Silver Creek Pharmaceuticals, Inc. convertible notes payable	$ 1,807		796			$ 1,807
Conversion of Silver Creek Pharmaceuticals, Inc. convertible notes payable (shares)	0				0	0		0	0
Other comprehensive income	$ 14							$ 14
Loss attributable to non-controlling interest	556		(556)						$ 556
Net loss	(130,685)								(130,685)
Balance at Dec. 31, 2013	$ (43,465)		337		$ 1,025	$ 527,779		$ (24)	$ (572,245)
Balance (in shares) at Dec. 31, 2013					102,523
Conversion option of convertible senior notes (shares)	0				0	0		0	0
Exercise of stock options and common stock warrants	$ 10,425				$ 42	$ 10,383
Exercise of stock options and common stock warrants (shares)					4,174
Stock-based compensation	13,197					13,197
Conversion of Silver Creek Pharmaceuticals, Inc. convertible notes payable	$ 678		366			$ 678
Conversion of Silver Creek Pharmaceuticals, Inc. convertible notes payable (shares)	0				0	0		0	0
Other comprehensive income	$ (50)							$ (50)
Loss attributable to non-controlling interest	634		(634)						$ 634
Net loss	(83,559)								(83,559)
Balance at Dec. 31, 2014	(102,140)		69		$ 1,067	$ 552,037		(74)	(655,170)
Balance (in shares) at Dec. 31, 2014					106,697
Exercise of stock options and common stock warrants	10,101				$ 54	10,047
Exercise of stock options and common stock warrants (shares)					5,360
Stock-based compensation	15,351					15,351
Issuance of common stock in a public offering, net of issuance costs	38,560				$ 38	38,522
Issuance of common stock in a public offering, net of issuance costs (shares)					3,814
Other comprehensive income	74							$ 74
Loss attributable to non-controlling interest	725		(725)						725
Issuance of preferred stock by Silver Creek Pharmaceuticals, Inc.		$ 1,188		$ 895			$ 1,188
Net loss	(147,787)								(147,787)
Balance at Dec. 31, 2015	$ (183,928)		$ 239		$ 1,159	$ 617,145			$ (802,232)
Balance (in shares) at Dec. 31, 2015					115,871